FCGR2B and autoimmune disease: The aforementioned research indicates that reinforcing the affinity of FcγRIIb with engineered Fc might have an advantage in the treatment of autoimmune diseases by the suppression of the activating signal of abnormal immune responses via the FcγRIIb-dependent inhibitory mechanisms [37,48,49,50,51,52,53,54,55,56,57].